Literature DB >> 30860258

A year-long immune profile of the systemic response in acute stroke survivors.

Amy S Tsai1, Kacey Berry2,3, Maxime M Beneyto1, Dyani Gaudilliere4, Edward A Ganio1, Anthony Culos1, Mohammad S Ghaemi1, Benjamin Choisy1, Karim Djebali1, Jakob F Einhaus1, Basile Bertrand1, Athena Tanada1, Natalie Stanley1, Ramin Fallahzadeh1, Quentin Baca1, Lisa N Quach2,3, Elizabeth Osborn2,3, Lauren Drag3, Maarten G Lansberg2,3, Martin S Angst1, Brice Gaudilliere1, Marion S Buckwalter2,3,5, Nima Aghaeepour1.   

Abstract

Stroke is a leading cause of cognitive impairment and dementia, but the mechanisms that underlie post-stroke cognitive decline are not well understood. Stroke produces profound local and systemic immune responses that engage all major innate and adaptive immune compartments. However, whether the systemic immune response to stroke contributes to long-term disability remains ill-defined. We used a single-cell mass cytometry approach to comprehensively and functionally characterize the systemic immune response to stroke in longitudinal blood samples from 24 patients over the course of 1 year and correlated the immune response with changes in cognitive functioning between 90 and 365 days post-stroke. Using elastic net regularized regression modelling, we identified key elements of a robust and prolonged systemic immune response to ischaemic stroke that occurs in three phases: an acute phase (Day 2) characterized by increased signal transducer and activator of transcription 3 (STAT3) signalling responses in innate immune cell types, an intermediate phase (Day 5) characterized by increased cAMP response element-binding protein (CREB) signalling responses in adaptive immune cell types, and a late phase (Day 90) by persistent elevation of neutrophils, and immunoglobulin M+ (IgM+) B cells. By Day 365 there was no detectable difference between these samples and those from an age- and gender-matched patient cohort without stroke. When regressed against the change in the Montreal Cognitive Assessment scores between Days 90 and 365 after stroke, the acute inflammatory phase Elastic Net model correlated with post-stroke cognitive trajectories (r = -0.692, Bonferroni-corrected P = 0.039). The results demonstrate the utility of a deep immune profiling approach with mass cytometry for the identification of clinically relevant immune correlates of long-term cognitive trajectories.
© The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  cognitive outcomes; machine learning; mass cytometry; stroke; systemic immunology

Mesh:

Substances:

Year:  2019        PMID: 30860258      PMCID: PMC6933508          DOI: 10.1093/brain/awz022

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  40 in total

Review 1.  What does Stat3 do?

Authors:  David E Levy; Chien-kuo Lee
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

2.  Therapeutic effect of IL-12/23 and their signaling pathway blockade on brain ischemia model.

Authors:  Fumie Konoeda; Takashi Shichita; Hideyuki Yoshida; Yuki Sugiyama; Go Muto; Eiichi Hasegawa; Rinpei Morita; Norihiro Suzuki; Akihiko Yoshimura
Journal:  Biochem Biophys Res Commun       Date:  2010-10-20       Impact factor: 3.575

Review 3.  Inflammatory mechanisms in ischemic stroke: role of inflammatory cells.

Authors:  Rong Jin; Guojun Yang; Guohong Li
Journal:  J Leukoc Biol       Date:  2010-02-03       Impact factor: 4.962

4.  Clinical recovery from surgery correlates with single-cell immune signatures.

Authors:  Brice Gaudillière; Gabriela K Fragiadakis; Robert V Bruggner; Monica Nicolau; Rachel Finck; Martha Tingle; Julian Silva; Edward A Ganio; Christine G Yeh; William J Maloney; James I Huddleston; Stuart B Goodman; Mark M Davis; Sean C Bendall; Wendy J Fantl; Martin S Angst; Garry P Nolan
Journal:  Sci Transl Med       Date:  2014-09-24       Impact factor: 17.956

Review 5.  The role of the transcription factor CREB in immune function.

Authors:  Andy Y Wen; Kathleen M Sakamoto; Lloyd S Miller
Journal:  J Immunol       Date:  2010-12-01       Impact factor: 5.422

6.  Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial.

Authors:  Jacob Elkins; Roland Veltkamp; Joan Montaner; S Claiborne Johnston; Aneesh B Singhal; Kyra Becker; Maarten G Lansberg; Weihua Tang; Ih Chang; Kumar Muralidharan; Sarah Gheuens; Lahar Mehta; Mitchell S V Elkind
Journal:  Lancet Neurol       Date:  2017-02-15       Impact factor: 44.182

Review 7.  Stroke-induced immunodepression: experimental evidence and clinical relevance.

Authors:  Ulrich Dirnagl; Juliane Klehmet; Johann S Braun; Hendrik Harms; Christian Meisel; Tjalf Ziemssen; Konstantin Prass; Andreas Meisel
Journal:  Stroke       Date:  2007-02       Impact factor: 7.914

8.  IL-6: an early marker for outcome in acute ischemic stroke.

Authors:  U Waje-Andreassen; J Kråkenes; E Ulvestad; L Thomassen; K-M Myhr; J Aarseth; C A Vedeler
Journal:  Acta Neurol Scand       Date:  2005-06       Impact factor: 3.209

9.  Blood levels of glial fibrillary acidic protein (GFAP) in patients with neurological diseases.

Authors:  Christoph A Mayer; Robert Brunkhorst; Marion Niessner; Waltraud Pfeilschifter; Helmuth Steinmetz; Christian Foerch
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

Review 10.  The immunology of stroke: from mechanisms to translation.

Authors:  Costantino Iadecola; Josef Anrather
Journal:  Nat Med       Date:  2011-07-07       Impact factor: 53.440

View more
  19 in total

Review 1.  In Vitro Oxygen Glucose Deprivation Model of Ischemic Stroke: A Proteomics-Driven Systems Biological Perspective.

Authors:  Manju Babu; Nikhil Singh; Arnab Datta
Journal:  Mol Neurobiol       Date:  2022-01-26       Impact factor: 5.590

2.  CD11bhigh B Cells Increase after Stroke and Regulate Microglia.

Authors:  Janelle M Korf; Pedram Honarpisheh; Eric C Mohan; Anik Banerjee; Maria P Blasco-Conesa; Parisa Honarpisheh; Gary U Guzman; Romeesa Khan; Bhanu P Ganesh; Amy L Hazen; Juneyoung Lee; Aditya Kumar; Louise D McCullough; Anjali Chauhan
Journal:  J Immunol       Date:  2022-06-22       Impact factor: 5.426

Review 3.  The Local and Peripheral Immune Responses to Stroke: Implications for Therapeutic Development.

Authors:  Kristy A Zera; Marion S Buckwalter
Journal:  Neurotherapeutics       Date:  2020-04       Impact factor: 7.620

4.  Role of B cells and the aging brain in stroke recovery and treatment.

Authors:  E B Engler-Chiurazzi; K L Monaghan; E C K Wan; X Ren
Journal:  Geroscience       Date:  2020-08-07       Impact factor: 7.713

Review 5.  Immune responses to stroke: mechanisms, modulation, and therapeutic potential.

Authors:  Costantino Iadecola; Marion S Buckwalter; Josef Anrather
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

Review 6.  Immunological mechanisms in poststroke dementia.

Authors:  Kristian P Doyle; Marion S Buckwalter
Journal:  Curr Opin Neurol       Date:  2020-02       Impact factor: 5.710

Review 7.  Infection as a Stroke Risk Factor and Determinant of Outcome After Stroke.

Authors:  Mitchell S V Elkind; Amelia K Boehme; Craig J Smith; Andreas Meisel; Marion S Buckwalter
Journal:  Stroke       Date:  2020-09-08       Impact factor: 7.914

8.  Obesity Drives Delayed Infarct Expansion, Inflammation, and Distinct Gene Networks in a Mouse Stroke Model.

Authors:  Todd C Peterson; Kendra J Lechtenberg; Brian D Piening; Tawaun A Lucas; Eric Wei; Hassan Chaib; Alexa K Dowdell; Michael Snyder; Marion S Buckwalter
Journal:  Transl Stroke Res       Date:  2020-06-25       Impact factor: 6.829

Review 9.  Age-related immune alterations and cerebrovascular inflammation.

Authors:  Carson E Finger; Ines Moreno-Gonzalez; Antonia Gutierrez; Jose Felix Moruno-Manchon; Louise D McCullough
Journal:  Mol Psychiatry       Date:  2021-10-28       Impact factor: 13.437

Review 10.  Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities.

Authors:  Karen D Davis; Nima Aghaeepour; Andrew H Ahn; Martin S Angst; David Borsook; Ashley Brenton; Michael E Burczynski; Christopher Crean; Robert Edwards; Brice Gaudilliere; Georgene W Hergenroeder; Michael J Iadarola; Smriti Iyengar; Yunyun Jiang; Jiang-Ti Kong; Sean Mackey; Carl Y Saab; Christine N Sang; Joachim Scholz; Marta Segerdahl; Irene Tracey; Christin Veasley; Jing Wang; Tor D Wager; Ajay D Wasan; Mary Ann Pelleymounter
Journal:  Nat Rev Neurol       Date:  2020-06-15       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.